This company has been acquired
La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Societal CDMO Résultats passés
Passé contrôle des critères 0/6
Societal CDMO's earnings have been declining at an average annual rate of -31.7%, while the Pharmaceuticals industry saw earnings growing at 1.6% annually. Revenues have been growing at an average rate of 0.8% per year.
Informations clés
-31.7%
Taux de croissance des bénéfices
-17.4%
Taux de croissance du BPA
| Pharmaceuticals Croissance de l'industrie | 6.0% |
| Taux de croissance des recettes | 0.8% |
| Rendement des fonds propres | -22.6% |
| Marge nette | -14.0% |
| Dernière mise à jour des bénéfices | 31 Dec 2023 |
Mises à jour récentes des performances passées
Recent updates
Societal CDMO, Inc.'s (NASDAQ:SCTL) Price Is Right But Growth Is Lacking After Shares Rocket 38%
Feb 10
Is There An Opportunity With Societal CDMO, Inc.'s (NASDAQ:SCTL) 46% Undervaluation?
Feb 02Is Societal CDMO (NASDAQ:SCTL) Weighed On By Its Debt Load?
Dec 23Does Societal CDMO (NASDAQ:SCTL) Have A Healthy Balance Sheet?
May 31Societal CDMO signs two CDMO service agreements
Oct 20Societal stock soars 20% on signing 2 manufacturing contracts
Sep 07Societal CDMO estimates to receive up to $50M on real estates' sales
Aug 16Societal CDMO, Lannett amend license and supply deal
Jul 12These 4 Measures Indicate That Societal CDMO (NASDAQ:SCTL) Is Using Debt Extensively
Apr 29Is Recro Pharma (NASDAQ:REPH) A Risky Investment?
Jan 06Recro Pharma jumps 15% on Q1 result estimates beat
May 07Would Shareholders Who Purchased Recro Pharma's (NASDAQ:REPH) Stock Year Be Happy With The Share price Today?
Feb 15
Ventilation des recettes et des dépenses
Comment Societal CDMO gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
| Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
|---|---|---|---|---|
| 31 Dec 23 | 95 | -13 | 21 | 0 |
| 30 Sep 23 | 91 | -22 | 21 | 0 |
| 30 Jun 23 | 89 | -20 | 21 | 0 |
| 31 Mar 23 | 91 | -20 | 21 | 0 |
| 31 Dec 22 | 90 | -20 | 22 | 0 |
| 30 Sep 22 | 88 | -13 | 20 | 0 |
| 30 Jun 22 | 85 | -13 | 20 | 0 |
| 31 Mar 22 | 80 | -9 | 18 | 0 |
| 31 Dec 21 | 75 | -11 | 17 | 0 |
| 30 Sep 21 | 63 | -21 | 17 | 0 |
| 30 Jun 21 | 64 | -19 | 17 | 0 |
| 31 Mar 21 | 62 | -27 | 17 | 0 |
| 31 Dec 20 | 66 | -28 | 18 | 0 |
| 30 Sep 20 | 74 | -21 | 18 | 0 |
| 30 Jun 20 | 80 | -14 | 18 | 0 |
| 31 Mar 20 | 96 | -3 | 19 | 0 |
| 31 Dec 19 | 99 | 5 | 20 | 0 |
| 30 Sep 19 | 99 | 35 | 1 | 0 |
| 30 Jun 19 | 92 | 17 | 4 | 0 |
| 31 Mar 19 | 83 | 0 | 11 | 0 |
| 31 Dec 18 | 77 | -13 | 14 | 0 |
| 30 Sep 18 | 79 | -63 | 38 | 0 |
| 30 Jun 18 | 77 | -58 | 38 | 0 |
| 31 Mar 18 | 73 | -54 | 31 | 0 |
| 31 Dec 17 | 72 | -7 | 14 | 0 |
| 30 Sep 17 | 70 | -36 | 20 | 0 |
| 30 Jun 17 | 70 | -33 | 18 | 0 |
| 31 Mar 17 | 70 | -32 | 14 | 0 |
| 31 Dec 16 | 69 | -30 | 13 | 0 |
| 30 Sep 16 | 69 | -9 | 14 | 0 |
| 30 Jun 16 | 68 | -6 | 13 | 0 |
| 31 Mar 16 | 70 | 1 | 13 | 0 |
| 31 Dec 15 | 52 | 3 | 13 | 0 |
| 30 Sep 15 | 35 | -11 | 10 | 0 |
| 30 Jun 15 | 19 | -14 | 7 | 0 |
| 31 Mar 15 | 0 | -15 | 6 | 0 |
| 31 Dec 14 | 0 | -17 | 4 | 0 |
| 30 Sep 14 | 0 | -14 | 3 | 0 |
| 30 Jun 14 | 0 | -10 | 2 | 0 |
| 31 Mar 14 | 0 | -8 | 1 | 0 |
| 31 Dec 13 | 0 | -2 | 1 | 1 |
| 30 Sep 13 | 0 | -2 | 1 | 1 |
Des revenus de qualité: SCTL is currently unprofitable.
Augmentation de la marge bénéficiaire: SCTL is currently unprofitable.
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: SCTL is unprofitable, and losses have increased over the past 5 years at a rate of 31.7% per year.
Accélération de la croissance: Unable to compare SCTL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Bénéfices par rapport au secteur d'activité: SCTL is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-13.2%).
Rendement des fonds propres
ROE élevé: SCTL has a negative Return on Equity (-22.63%), as it is currently unprofitable.